14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. - Wikidata - wikimedia - TriplyDB

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

http://www.wikidata.org/entity/Q35855301

about

Optimum duration of regimens for Helicobacter pylori eradication Sequential versus standard triple first-line therapy forHelicobacter pylorieradication Treatment of Helicobacter pylori infection: Current and future insights Antibiotic treatment for Helicobacter pylori: Is the end coming?Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis Chinese Helicobacter pylori vaccine: Solution for an old challenge?Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages Treatment of Helicobacter pylori infection: Where are we now?Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention Treatment of Helicobacter pylori infection: current status and future concepts.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale."Concomitant" or "sequential" eradication of Helicobacter pylori: which regimen comes first?First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: a systematic review.Treatment of Helicobacter pylori infection: Past, present and future Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial.The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study.Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Newer agents for Helicobacter pylori eradication Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.The Globalization of Cooperative Groups.7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan.Helicobacter pylori Eradication Therapy: Current Availabilities.Preclinical evaluation of anti-Helicobacter spp. activity of Hippocratea celastroides Kunth and its acute and sub-acute toxicity Helicobacter pylori therapy: Present and future The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting.Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.Latin America: ripe for cutting-edge research proposals for prevention and control of Helicobacter pylori.The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities

P2860

Q24201841-E672E81B-7FAF-4FC3-9D8D-01ABA858CDE1 Q26471410-EDFE7F8C-DF4D-4508-AB0C-DE5F927CA164 Q26769707-1FD6A2FC-F04B-4134-BCD7-575FF4232161 Q26777623-5E7ED50F-49AA-40DD-B7A3-908C10F66C02 Q26778023-212A20B2-CF80-4D07-8F4A-3DC13448F6B2 Q26796367-264789A0-18A9-4C24-B332-0869BFBD39B2 Q28077515-88E44183-00C4-42AD-BFB4-36F0D22DB7CA Q28296156-2BCF23A2-3C9C-473A-8703-00F6845811C2 Q28545933-933F64FE-70CA-4DA5-B9F7-47AE5F9AFC7C Q30251567-FB18F8F7-7B25-4806-B18D-9443D1432862 Q33560119-F8C6EBC1-BBD3-49EA-A1E3-4029941B9B62 Q33594850-B9D55C0E-0A3D-4B8C-8B09-4C254152CA9A Q33698340-9124149F-0D77-4612-9AC4-F8C6103920A8 Q33813453-752A4257-4B46-4B20-9923-B87E6180E58A Q33822948-B206E1A3-4EA1-4AAC-91D0-C19A060A2E46 Q34067951-89054C06-33AB-4DA7-8001-4B77D869B0D5 Q34167285-52607085-9C46-49BF-B5AE-F02E59DEF977 Q34299125-7C4E189C-DF41-4B3E-AC4A-2E71F4C99223 Q34404967-A4ACA083-F073-4571-BAA9-0CF9314F1FED Q34508830-6FC07E27-6DFC-444C-B940-F232825C2157 Q35015521-2AFD7B65-1026-41EF-83CE-2E0B8963E61B Q35498491-6D6C3BC9-C86D-47FF-A71D-443E943483BB Q35614400-A7A065AC-D326-4C5B-A160-5BEF4A69C99C Q35830094-3C8D7CB9-7C85-4EC0-A406-8410274F40EF Q35841617-FA93B39B-A3F2-4880-B1DF-9D740516CBF6 Q36071019-BCCC38C1-4A90-4A51-AA89-69CC19297B29 Q36085602-56AE8DA0-2AF4-479A-8FA3-A687AD088593 Q36119749-03406384-59CD-472B-A953-D55E4312B510 Q36129001-13AD1D49-040D-498B-BF40-02041E70342B Q36148148-2DD31957-BF42-428E-818E-AB0E4AB14D6B Q36186076-A6B5E5EB-9785-457C-B3B0-E3CF6939837A Q36220182-2877DEC0-82F4-430F-B14F-617397CD74D8 Q36402306-04D55F9C-6B4E-4485-AEB9-17DE3F7B00F6 Q36412858-C351BE38-9AD8-4034-88C1-54A678CE0424 Q36425705-66784383-6D4D-448B-880B-77DC4F93A9AE Q36503818-3DF4B478-EBF1-4273-A90C-9433BC5CECCE Q36566269-F0E3B0C1-A93D-49EE-98EB-848B97ED8263 Q36745832-BBBC804A-C118-4722-AAF3-6489E3938B2A Q36819921-EBC03038-7802-4E11-A6B4-E71C89982212 Q36972107-2B95003E-BA03-4668-AAC9-942D3127C155

P2860

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

http://www.wikidata.org/entity/Q35855301

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@ast

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@en

type

label

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@ast

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@en

prefLabel

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@ast

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@en

P1433

Q35855301-4D557526-46CD-47B0-BBC4-29664E2614AF

P1476

Q35855301-2EE1E31C-83B9-44EC-B387-4582F22D63BE

P2093

Q35855301-0BEE190F-95D4-4E1E-8C0A-C110E53456D7

Q35855301-13FE2F8E-4B24-4258-8033-ECA705745123

Q35855301-385FDB8A-D06D-4F1C-8A8E-F9049962C760

Q35855301-3CB1B9BB-5767-48FD-826C-03B19D999241

Q35855301-3F6B8978-24A7-4720-8E29-4495BEFB0D83

Q35855301-4D9AF39D-BF3B-4A11-BD96-CE16F18089A7

Q35855301-4E9CE02B-7DD4-4F0C-9624-D9991B24FA71

Q35855301-551AA2BF-7594-4CDB-A544-613F665EC2AB

Q35855301-71621E5C-A6C8-4BCD-B952-10E932637AA5

Q35855301-73323FFD-DF01-4461-B825-245F97F04E43

P2860

Q35855301-0BFB217E-F6EE-42D7-9120-A49421A63878

Q35855301-149C335A-64D3-49C8-9890-39B832C33367

Q35855301-26379A3C-A4D4-4D9D-820E-01AF809A813C

Q35855301-2D77FD81-8F2B-411D-B278-18A4274BF198

Q35855301-331403DA-C424-470D-A7D4-2094DA66540C

Q35855301-496CB7B9-0BAC-483B-8426-48B7AE415D24

Q35855301-54E990D3-03B9-4C5D-AD20-929953EC4065

Q35855301-5A7DEE10-41F1-43A3-8AEB-EADF608B46B8

Q35855301-6E397E87-F3EB-4347-990F-65A04575A195

Q35855301-7431C0FD-75B0-426D-A639-3EEB63642C95

P304

Q35855301-DD11F77D-69CC-4847-96D6-8385F2A34348

P31

Q35855301-C7209740-7AAC-4F2B-97AD-A250FF210470

P356

Q35855301-E3F75ACF-BA7C-4EE6-BC6C-D754AD9ADAC6

P407

Q35855301-F3EB4BDE-101B-4949-B993-37BF591658B0

P433

Q35855301-8B38A261-74DA-4E62-BE15-6863193EB3CE

P478

Q35855301-1A4F33CA-C374-4898-A8BA-C8280972CA40

P50

Q35855301-6957A7A3-EB9B-413D-A9C3-750ED87371E3

P577

Q35855301-73B1D38E-1630-4F1A-A5BD-5DA90AE655E3

P5875

Q35855301-0DA0EE45-37CC-4323-BC16-9E580CD34B48

P698

Q35855301-255933B6-E2C8-4713-90F3-536C9E6A48D1

P921

Q35855301-8F219680-2211-413F-BC99-680BFB0D042B

P932

Q35855301-F0F8899B-7941-4253-B29E-12030688A602

P356

S0140-6736(11)60825-8

P1433

P1476

14-day triple, 5-day concomita ...... can sites: a randomised trial.

@en

P2093

Douglas R Morgan

http://www.w3.org/2001/XMLSchema#string

E Robert Greenberg

http://www.w3.org/2001/XMLSchema#string

Edgar M Peña

http://www.w3.org/2001/XMLSchema#string

Eduardo C Lazcano-Ponce

http://www.w3.org/2001/XMLSchema#string

Eduardo Salazar-Martínez

http://www.w3.org/2001/XMLSchema#string

Garnet L Anderson

http://www.w3.org/2001/XMLSchema#string

Gary E Goodman

http://www.w3.org/2001/XMLSchema#string

Javier Torres

http://www.w3.org/2001/XMLSchema#string

John J Crowley

http://www.w3.org/2001/XMLSchema#string

Laurence H Baker

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

New concepts of resistance in the treatment of Helicobacter pylori infections

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

H pylori antibiotic resistance: prevalence, importance, and advances in testing

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Functional gastroduodenal disorders

The global health burden of infection-associated cancers in the year 2002

The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.

P304

507-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)60825-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

9790

http://www.w3.org/2001/XMLSchema#string

P478

378

http://www.w3.org/2001/XMLSchema#string

P50

Catterina Ferreccio

P577

2011-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51510472

http://www.w3.org/2001/XMLSchema#string

P698

21777974

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori

P932

3313469

http://www.w3.org/2001/XMLSchema#string